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Programmed death-1 (PD-1) is a known immunoinhibitory receptor that contributes to immune evasion of various
tumor cells and pathogens causing chronic infection, such as bovine leukemia virus (BLV) infection. First, in this
study, to establish a method for the expression and functional analysis of bovine PD-1, hybridomas producing
monoclonal antibodies (mAb) specific for bovine PD-1 were established. Treatment with these anti-PD-1 mAb
enhanced interferon-gamma (IFN-γ) production of bovine peripheral blood mononuclear cells (PBMC). Next, to
examine whether PD-1 blockade by anti-PD-1 mAb could upregulate the immune reaction during chronic infection,
the expression and functional analysis of PD-1 in PBMC isolated from BLV-infected cattle with or without lymphoma
were performed using anti-PD-1 mAb. The frequencies of both PD-1+ CD4+ T cells in blood and lymph node and
PD-1+ CD8+ T cells in lymph node were higher in BLV-infected cattle with lymphoma than those without
lymphoma or control uninfected cattle. PD-1 blockade enhanced IFN-γ production and proliferation and reduced
BLV-gp51 expression and B-cell activation in PBMC from BLV-infected cattle in response to BLV-gp51 peptide
mixture. These data show that anti-bovine PD-1 mAb could provide a new therapy to control BLV infection via
upregulation of immune response.Introduction
Immunoinhibition is considered one of the reasons re-
sponsible for the refractory nature of several types of tu-
mors and chronic infections [1,2]. One of them, bovine
leukemia virus (BLV) is known to induce immunosup-
pression and B cell lymphoma in cattle, and lead to
enormous damages to livestock industries around the
world [3]. BLV establishes a chronic infection in B cells
for several years until infected cattle develop B-cell
lymphoma mainly in lymphoid tissue, although neither
viral RNA nor protein expression was readily detected
in vivo or freshly isolated lymphocytes [4,5]. During the
chronic infection, the suppression of both CD4+ T cell
proliferation and cytotoxic immune response against
BLV antigens is correlated to disease progression [3,6].
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reproduction in any medium, provided the orinfection, the mechanism responsible for this immuno-
suppression needs to be clarified.
Programmed death-1 (PD-1) has been recognized as
being at the heart of peripheral immune tolerance and
pathogen-specific immunoinhibition [2]. In various types
of chronic infections and tumors, PD-1 and its ligand,
PD-ligand-1 (PD-L1) play an important role in inhibiting
chronically activated T cells specific for pathogens,
resulting in the induction of “exhausted” T cells [5,7-9].
Treatment with monoclonal antibodies (mAb) specific
for either PD-1 or PD-L1 reactivates exhausted immune
responses such as proliferation, cytokine production,
and cytotoxic capabilities of exhausted T cells ex vivo
[7,10], and in vivo [11,12], and was tested in clinical tri-
als with cancer patients [13,14].
In the field of veterinary medicine, the PD-1/PD-L1
pathway was also investigated in the pig [15,16], chicken
[17] and cat [18] and found to contribute to pathogen-
esis and immune evasion of chronic infectious diseases.
Our previous reports also showed that the expression ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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upregulated in BLV-infected (BLV+) cattle as the disease
progressed, and PD-L1 blockade upregulated expressions
of interferon-gamma (IFN-γ) and interleukin (IL)-2
mRNA in peripheral blood mononuclear cells (PBMC)
in vitro [19]. The expression levels of PD-1 mRNA were
upregulated in CD4+ and CD8+ T cells isolated from
BLV+ cattle with B-cell lymphoma (BCBL) [20].
In previous reports, anti- “human” PD-1 or PD-L1
“polyclonal” antibodies (pAb) were used to analyze their
expression and to block the PD-1/PD-L1 pathway
[18,19]. Under some experimental conditions, anti-PD-1
pAb induced IL-10 production by monocytes, resulting
in the inhibition of CD4+ T cell function [21]. However,
at the present time, mAb specific for animal PD-1 and
PD-L1 which can reactivate exhausted immune reaction
are not available, although they are essential for further
investigation and development of new therapy for refrac-
tory diseases, such as BLV infection. In this study anti-
bovine PD-1 mAb were established and their functional
capabilities were assessed using PBMC from BLV+ and
BLV-uninfected (BLV-) cattle in vitro. The upregulation
of PD-1 expression was found in CD4+ and CD8+ T cells
isolated from BCBL. The treatment with an anti-PD-1
mAb upregulated IFN-γ production and reduced both B
cell activation and BLV-gp51 expression in PBMC iso-
lated from BLV+ cattle. These data suggest that anti-PD
-1 mAb can be applicable for antibody drug to control
BLV infection.
Materials and methods
Construction and expression of recombinant soluble
bovine PD-1-immunoglobulin fusion protein
Soluble PD-1-bovine IgG1 fusion protein (PD-1-Ig) was
expressed in a mammalian cell expression system. The
extracellular domain fragment of bovine PD-1 was ampli-
fied and the fragment was inserted into the cloning site of a
modified pCAGGS (provided by Dr J. Miyazaki, Osaka
University; [22]) that contained a mouse CD150 leader se-
quence at the N terminus and the Fc fragment of bovine
IgG1 at the C terminus [23]. PD-1-Ig was produced in
Cos-7 cells transfected transiently by Lipofectamine 2000
(Life Technologies, Carlsbad, CA, USA) and purified from
the media with Protein G Sepharose 4 Fast Flow (GE
Healthcare UK Ltd, Buckinghamshire, UK) according to
the manufacturer’s protocol. The expression and purifica-
tion of PD-1-Ig was confirmed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
enzyme-linked immunosorbent assay (ELISA) using anti-
bovine IgG-Fc (Rockland Immunochemicals, PA, USA).
Generation and screening of mAb specific for bovine PD-1
To obtain mAb specific for bovine PD-1, a rat was im-
munized with about 66 μg of PD-1-Ig and completeFreund adjuvant. Nineteen days later, 100 μg of PD-1-Ig
was shot into the rat as a boost. On the 24th day of the
first immunization, lymphocytes isolated from the iliac
lymph node (LN) were fused with myeloma cells and
cloned, and the supernatants from hybridomas were
screened by ELISA for the reactivity of culture super-
natant with PD-1-Ig. Clones that produce antibodies
specific for bovine IgG1-Fc were excluded by ELISA
using bovine IgG as an antigen. The immunization of
rats and ELISA was performed at Cell Engineering Cor-
poration (Osaka, Japan). The hybridomas were also
screened by flow cytometry using Cos-7 cells that were
transfected with bovine PD-1 coding pCMV-Tag-1
(Agilent Technologies, CA, USA). Hybridomas produ-
cing antibodies that reacted with transfected but not
untransfected PD-1 Cos-7 cells were cloned by limiting
dilution.
Western blotting
To test the reactivity of anti-bovine PD-1 mAb, Western
blot analysis was performed using Chinese hamster
ovary (CHO)-DG44 cells (provided by Dr Y. Suzuki) that
stably express bovine PD-1. CHO-DG44 cells were
transfected with bovine PD-1 coding pCMV-Tag-1 using
Lipofectamine Ltx (Life Technologies). Transfectants
were selected in CD-DG44 (Life Technologies)
containing G418 sulfate (Wako, Osaka, Japan; 800 μg/
mL) for two weeks. The cells were then incubated with
anti-bovine PD-1 mAb (produced from our hybridoma,
5D2), followed by incubation with Anti-Rat IgG Micro
beads (Miltenyi Biotec, Bergisch Gladbach, Germany).
CHO-DG44 cells highly expressing PD-1 were sorted by
auto MACS Pro (Miltenyi Biotec), cultivated for a week,
and then re-sorted. CHO cells transfected with non-
coding pCMV-Tag-1 were selected in the same way and
used as a negative control. The cells were lysed in 2×
SDS buffer (125 mM Tris–HCl pH 6.8, 4% SDS, 10%
2-mercaptoethanol, and 20% glycerol) and boiled
for 10 min. The samples were separated on 12%
SDS-polyacrylamide gels and transferred onto a
polyvinylidene difluoride membrane (Merck Millipore,
MA, USA). After being blocked with 3% skim milk in
phosphate-buffered saline (PBS, pH 7.2) containing
0.05% Tween 20 (PBS-T), the membranes were incu-
bated at room temperature for 2 h with anti-PD-1
mAb (2C12 and 3G2: 3 μg/mL, 2H7 and 5D2: 1 μg/
mL), followed by washing and incubation with horse
radish peroxidase (HRP)-conjugated anti-rat IgG (MP
Biomedicals, CA, USA). The membrane was also
probed with anti-Actin antibody (Merck Millipore;
clone C4) and anti-myc tag antibody (Abcam,
Cambridge, UK; goat polyclonal antibody) as loading
control and positive control. After washing, the mem-
branes were incubated with Immobilon Western
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to visualize signals, and analyzed with a Fluor-S Multi
Imager (Bio-Rad Laboratories, CA, USA).Samples from cattle and BLV diagnosis
Blood and mesenteric LN samples from Japanese black
and Holstein-Friesian were investigated. In this study,
we obtained blood samples from 95 cattle altogether
(BLV+: 53, BLV-: 42) bred on several farms. They were
collected in about ten installments. Peripheral venous
blood was collected from cows into tubes containing so-
dium heparin (Ajinomoto, Tokyo, Japan). All of the cat-
tle from which the blood samples were obtained had
been diagnosed with BLV infection by nested PCR as
described previously [19] at the Veterinary Teaching
Hospital, Graduate School of Veterinary Medicine, Hok-
kaido University between 2008 and 2012. LN samples
were provided by the Meat inspection center and veter-
inary hospitals in Japan, and diagnosed by nested-real
time PCR using primers described previously [19].
The first amplification was conducted by KOD FX neo
(Toyobo, Osaka, Japan) using less than 20 000 LN
cells as templates, and the second amplification was
performed using SYBR Premix DimerEraser (Takara,
Shiga, Japan). This study was conducted in accordance
with the guidelines of the Institutional Animal Care and
Use Committee of Hokkaido University, Japan. Samples
were collected after informed consent was obtained from
farmers.
To diagnose B cell lymphoma, phenotypic analysis of
PBMC and/or tumor-bearing LN (mesenteric, iliac, gas-
tric or superficial cervical LN) cells from BCBL which
had been diagnosed clinically were performed by flow
cytometry. Double staining were conducted using anti-
bovine IgM (BIG73A; VMRD, WA, USA) pre-labeled
with Zenon Alexa Fluor 488 (Life Technologies) and the
following antibodies; anti-WC4 (CC55; CD19 like; AbD
Serotec, Oxford, UK) [24], anti-B-B7 (GB25A; CD21 like;
VMRD) and anti-bovine CD5 (CACT105A; VMRD).
Alexa Fluor 647-conjugated anti-mouse IgG (Life Tech-
nologies) was used for the antibodies other than anti-
IgM as a secondary antibody. The samples in which
more than 85% of the cells were B cells (IgM+ CD5+,
IgM- WC4+ or IgM- CD21+) were diagnosed as B-cell
lymphoma induced by BLV. More than 30 000 lympho-
cytes were analyzed.Cell preparation from blood and lymph nodes
PBMC were purified from the blood samples by density
gradient centrifugation on Percoll (GE Healthcare UK
Ltd). LN tissues were minced in PBS and passed through
a cell strainer (40 μm; BD Biosciences, NJ, USA).PD-1 expression analysis
To block nonspecific staining, 5–20 × 105 PBMC were
incubated in PBS containing 10% goat serum
(Sigma-Aldrich, MO, USA) at room temperature for
15 min. The cells were then washed and stained for PD-
1, CD4, CD8, IgM and CD25 for 30 min at room
temperature. The following antibody conjugates were
used in Figure 1: PD-1:5D2; CD4:CACT138A (VMRD)
pre-labeled with Zenon Alexa Fluor 488; CD8:CACT80C
(VMRD) pre-labeled with Lightning-Link PerCP/Cy5.5
(Innova Biosciences, Cambridge, UK); IgM:BIG73A pre-
labeled with Zenon PE (Life Technologies); CD25:
CACT116A pre- labeled with Lightning-Link PE-Cy7
(Innova Biosciences). In Figure 2, the cells were stained
with the following antibody: PD-1, CD4 pre-labeled with
Zenon Alexa Fluor 488, CD8 pre-labeled with
Lightning-Link PerCP/Cy5.5, and IgM pre-labeled with
Lightning-Link PE-Cy7. After washing with PBS
containing 10% goat serum, the cells were incubated
with APC-conjugated anti-rat IgM + IgG (Beckman
Coulter, CA, USA) for 30 min at room temperature. The
cells were then washed and immediately analyzed by
FACS Verse (BD Biosciences) and FCS Express 4 (De
Novo Software, CA, USA). No fewer than 40 000 lym-
phocytes and no more than 160 000 lymphocytes were
analyzed among the samples.
To measure the upregulation of PD-1 expression in
stimulated bovine lymphocytes isolated from BLV- cattle,
PBMC were cultivated for 24, 48, and 72 h at 37 °C with
5% CO2 in RPMI-1640 in the presence of pokeweed
mitogen (PWM, 5 μg/mL, Sigma-Aldrich) or phorbol
12-myristate acetate (PMA) and ionomycin (20 ng/mL
and 1 μg/mL; Sigma-Aldrich). No fewer than 13 000
lymphocytes and no more than 36 000 lymphocytes were
analyzed among the samples.
Analysis of PD-L1 expression in BLV-gp51 positive cells
To confirm PD-L1 expression in BLV+ cells, intracellular
staining was performed. PBMC isolated from BLV+ or
BLV- cattle were cultivated for 18 h, and the cells were
stained by anti-human PD-L1 (Santa Cruz Biotechnol-
ogy, CA, USA) and anti-bovine IgM as previously de-
scribed [19]. After surface staining, the cells were fixed
and permealized by FOXP3 Fix/Perm kit (BioLegend,
Cambridge, UK) according to the manufacturer’s proto-
col. Then, the cells were stained with anti-gp51 (BLV1;
VMRD) pre-labeled with Zenon PE, washed and imme-
diately analyzed. More than 30 000 lymphocytes were
analyzed.
PD-1 blockade assay
To determine the effect of the immune activation by
anti-PD-1 mAb, bovine PBMC were cultured with
20 μg/mL of anti-PD-1 mAb or rat IgG (Sigma-Aldrich)
Figure 1 Recognition of PD-1-expressing cells by anti-PD-1 mAb. (a) Flow cytometric analysis of surface expression of bovine PD-1. Cos-7
expressing PD-1 (black line) and Cos-7 transfected with the control vector (dashed line) were stained with four types of anti-PD-1 mAb (2C12,
2H7, 3G2, and 5D2) and isotype control (Rat IgG). (b) Western blotting analysis of bovine PD-1 expression in CHO-DG44 cells stably expressing
bovine PD-1. Three types of anti-PD-1 mAb recognized PD-1 (triangle) at about 68 kDa. Anti-actin antibody and anti-myc antibody was used as a
loading control and a positive control.
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presence of 10 μg/mL BLV-gp51 peptide mixture (15
mer). The peptide mixture covering the entire length of
gp51 and overlapping by 11 amino acids, were synthe-
sized in Hokkaido System Science (Hokkaido, Japan).
Flag peptide (DYKDDDDK) was used as the negative
control for gp51 peptide mixture. After 2 days, the cells
were collected for detection of apoptosis and expression
analysis of gp51, WC4 and CD80. The supernatants
were harvested and analyzed by ELISA. For real-time
PCR or cell proliferation assay, cultivated cells were
collected after 1 day or 5 days. In a portion of experi-
ments, isolated B cells from PBMC were cultured.
PBMC were incubated with anti-bovine IgM, and IgM+
B cells were isolated by autoMACS Pro and anti-mouse
IgG1 MicroBeads (Miltenyi Biotec).
IFN-γ and IL-10 ELISA
The production of IFN-γ in supernatants was measured
by ELISA for bovine IFN-γ (Mabtech, Nacka Strand,
Sweden) according to the manufacturer’s protocol. The
results were calculated based on a standard curve ran-
ging from 7.8 pg/mL to 500 pg/mL. Sandwich ELISA of
IL-10 was performed with two antibodies; anti-IL-10
(CC318; AbD Serotec) as capture antibody and biotin-
conjugated anti-IL-10 (CC320; AbD Serotec) as the de-
tective antibody. Briefly, 96 well plates were coatedovernight with CC318 diluted with PBS. After washing
with PBS and blocking by PBS-T containing 0.1% bovine
serum albumin (Sigma-Aldrich), the samples were incu-
bated in the wells for 2 h. Following washing, diluted de-
tective antibodies (CC320) were added to the wells and
incubated for 1 h. After further washing, Neutra-Avidin
-HRP was added and incubated for 1 h. Finally, the
plates were washed and incubated with TMB One
Component Substrate (Bethyl Laboratories, TX, USA),
and absorbance was measured by MTP-650FA (Corona
Electric, Ibaraki, Japan). A standard curve was constructed
using plasma which was separated from a cattle-derived
blood stimulated with 10 μg/mL concanavalin A (Sigma-
Aldrich) and 10 μg/mL lipopolysaccharide (Sigma-Aldrich)
for 48 h. The 1 (64) arb. unit is defined in terms of the
amount of IL-10 in 15.625 (1000) μL of the stimulated
plasma. Reported values represent the mean of duplicate
samples.
Cell proliferation assay
To investigate the effect of PD-1 blockade on the prolif-
eration of PBMC, a CFSE proliferation assay was
performed. In summary, PBMC were incubated with
2 μM CFSE (Life technologies) diluted with PBS at 37 °C
for 15 min, washed with RPMI-1640 three times and
cultured for 5 days. Then, the cells were stained with
anti-IgM pre-labeled with Lightning-Link PE-Cy7 and
Figure 2 (See legend on next page.)
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Figure 2 Recognition of PD-1-expressing lymphocytes by anti-PD-1 mAb. (a) Gating strategies for CD4+ T cells, CD8+ T cells and IgM+ B
cells in bovine lymphocytes. (b) Representative histograms obtained by flow cytometry of PD-1 expression in CD4+ T cells, CD8+ T cells and IgM+
B cells isolated from three BLV- cattle. Freshly isolated PBMC were stained with anti-PD-1 (5D2), CD4, CD8, and IgM Ab. PBMC were cultivated
with PBS (No stimulation), PMA/ionomycin, and PWM for 24, 48, and 72 h, and stained in a similar way. (c) Proportions of PD-1 positive cells in
CD4+ T cells, CD8+ T cells and IgM+ B cells. Statistical comparisons between percentages of PD-1 positive cells stimulated with PBS and PMA/
ionomycin or PWM were made using two way ANOVA. Differences were considered statistically significant at P < 0.05 (** P < 0.01). (d)
Representative dot plots of PD-1 and CD25 expression in CD4+ T cells, CD8+ T cells and IgM+ B cells 48 h after cultivation.
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CFSElo IgM- lymphocytes were measured for evaluation
of the proliferation of lymphocytes other than B cells.
No fewer than 2500 and no more than 14 000 lympho-
cytes other than B cells were analyzed among the
samples.
Expression analysis of BLV-gp51, WC4 and CD80
To analyze the effect of PD-1 blockade on B cell func-
tion, cultivated PBMC were stained with anti-IgM pre-
labeled with Zenon Alexa Fluor 488 and anti-WC4 or
anti-CD80 (AbD Serotec) or anti-BLV-gp51. Alexa Fluor
647-conjugated anti-mouse IgG was used for anti-WC4
and anti-CD80 as a secondary antibody. BLV-gp51 stain-
ing of either PBMC or isolated B cells was performed as
described above. Appropriate isotype controls were
performed with each sample. More than 20 000 lympho-
cytes were analyzed.
Real-time PCR
Total RNA was extracted from cultivated PBMC by
RNeasy Plus Mini Kit (QIAGEN, CA, USA), and cDNA
was synthesized by Reverse Transcriptase M-MLV
(Takara) following the manufacturer’s instructions.
Quantitative RT real-time PCR was performed using the
LightCycler 480 system II (Roche Diagnostics, Mann-
heim, Germany) according to the manufacturer’s in-
structions. Primers used for the amplification of BAFF
cDNA were 5’- CCA AGC TGG AGG AAG GAG ATG
AAC TC-3’ and 5’- CTC CAT CTC GGG ATA TCT
TAG CAT C-3’. The amount of BAFF mRNA expression
was divided by the expression of GAPDH and β-actin
mRNA as internal control genes. Each amplification
procedure was done in duplicate, and the results were
indicated as relative change to control (no antibody
treatment).
Detection of apoptosis
To detect apoptotic B cells, cultivated PBMC were
stained with anti-IgM as a first antibody and Alexa Fluor
647-conjugated anti-mouse IgG as a secondary antibody.
Following washing, cells were incubated with Annexin
V-FITC (Beckman Coulter) for 15 min and added 7-
AAD (BD Biosciences). No fewer than 12 000 lympho-
cytes and no more than 20 000 lymphocytes wereanalyzed among samples. The results are presented as
percentages of FITC+ 7-AAD- cells in total IgM+ B cells.
Statistical analysis
The Spearman rank-correlation, one-way ANOVA with
Tukey’s post test, two-way ANOVA and Wilcoxon
matched pairs test were performed using GraphPad
Prism version 5.0. P values < 0.05 were considered statis-
tically significant.
Results
Anti-PD-1 mAb react with PD-1-expressing cells
Supernatants containing antibody from 576 hybridoma
colonies were screened for their binding to bovine IgG
and PD-1-Ig by ELISA. Hybridomas that produced
mAb-recognizing bovine IgG were excluded. Four hy-
bridomas (2C12, 2H7, 3G2, and 5D2) were cloned and
confirmed as clones producing mAb that reacted with
Cos-7 expressing PD-1 but not with cells transfected
with the control vector (Table 1 and Figure 1a). Control
antibody (Rat IgG) did not react with both of the cells.
The degree of fluorescent signals of 2H7 and 5D2 were
different from those of 2C12 and 3G2. Anti-PD-1 mAb,
except for 2C12, were able to recognize heat-denatured
PD-1 at approximately 68 kDa by Western blotting,
showing that 2C12 could recognize a conformational
epitope of bovine PD-1 (Figure 1b).
Anti-PD-1 mAb react with bovine lymphocytes
To confirm that anti-PD-1 mAb can recognize bovine
PD-1 naturally expressed on bovine lymphocytes, we ex-
amined surface PD-1 expression on CD4+ and CD8+ T
cells as well as IgM+ B cells freshly isolated or stimulated
by mitogens, such as PWM and PMA/ionomycin
in vitro. An example of the gating strategy is shown in
Figure 2a. IgM+ B cells were first gated and IgM- cells
further analyzed for CD4 and CD8 expression. Amongst
the four anti-PD-1 mAb, the strongest fluorescence was
observed in PBMC stained with 5D2 (data not shown);
therefore, the cells were stained with 5D2 for subsequent
expression analyses of bovine PD-1. PD-1 was expressed
mainly on CD4+ T cells from freshly isolated PBMC,
whereas CD8+ T cells and B cells barely expressed PD-1
(Figure 2b).
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gen, PD-1 expression in lymphocytes was elevated,
whereas in vitro incubation without any stimulant did
not affect PD-1 expression in any population of lympho-
cytes (Figure 2b, c). PMA/ionomycin stimulation more
quickly induced PD-1 expression than in the case of no
stimulant, which was strongly enhanced in more than
90% of CD4+ and CD8+ T cells and half of B cells at
72 h (Figure 2b). Although PWM stimulates both T and
B cells [25] like PMA/ionomycin, on one level or an-
other, subsets of CD4+ and CD8+ T cells stimulated by
PWM expressed less PD-1 antigen than PBMC treated
with PMA/ionomycin at the same point in time, and the
rate of the upregulation in PWM stimulation was also
slower. Furthermore, upregulation of PD-1 expression
on B cells was not induced by PWM stimulation. In the
case of any stimulation, CD4+ T cells were prone to
more quickly upregulate PD-1 expression than CD8+ T
cells and B cells.
A previous report revealed that activated lymphocytes
express PD-1 antigen in mice [26]; therefore bovine PD-
1 expression on stimulated lymphocytes detected by a
classical activation marker, CD25, was evaluated. Forty-
eight hours after PMA/ionomycin stimulation, CD25 ex-
pression was strongly upregulated in either CD4+ and
CD8+ T cells and IgM+ B cells, and almost all T cells
and subset of B cells expressed PD-1 (Figure 2d). Other-
wise, under PWM stimulation, CD25 expression varied
widely among the subsets. Moreover, CD4+ CD25- T
cells expressed PD-1, but CD8+ CD25- T cells barely did.
We examined PD-1 expression in PBMC isolated from
three healthy cattle and similar results were obtained in
each case.
Anti-PD-1 mAb activate IFN-γ production
To clarify the function of mAb that inhibit the PD-1
/PD-L1 pathway and the inhibitory signal from PD-1, we
performed a PD-1 blockade assay. PBMC isolated from
BLV- cattle were cultured for 48 h in the presence of
each anti-PD-1 mAb or control antibody, and IFN-γ
production was then measured in the supernatants using
ELISA. All of the four anti-PD-1 mAb significantly in-
creased IFN-γ production in PBMC in comparison to
those treated with control rat IgG (Figure 3a). The treat-
ments of 2H7 and 5D2 upregulated the production ofIFN-γ in all sample cases. Furthermore, in PBMC culti-
vated with PMA/ionomycin in vitro, 2C12 and 5D2, but
not 2H7 and 3G2, significantly enhanced IFN-γ produc-
tion (Figure 3b), showing that the function of activated
lymphocytes by PMA/ionomycin stimulation could be
additionally enhanced by PD-1 blockade with 2C12 or
5D2 treatment. The most effective mAb was not deter-
mined because there were individual differences in INF-
γ production, and no significant difference was observed
within the degree of enhancement of IFN-γ production
induced by the treatment with the four mAb.
PD-1 expression is upregulated in CD4+ and CD8+ T cells
in BLV+ cattle with lymphoma
Our previous reports claimed that PD-1 mRNA expres-
sion in T cells isolated from BCBL was higher than from
BLV- cattle [20]. To confirm the PD-1 expression on the
cell surface of T cells in BLV+ cattle, flow cytometric
analysis was performed in PBMC and mesenteric (BLV-
and BLV+ cattle) or tumor-bearing (BCBL) LN cells
using anti-PD-1 mAb, 5D2. In blood, the mean percent-
ages of PD-1+ CD4+ T cells were higher in cattle with
lymphoma than in BLV+ and BLV- cattle (Figure 4a).
Meanwhile, in LN cells, the rates of PD-1 expression in
both CD4+ and CD8+ T cells were significantly higher in
BCBL than in BLV+ and BLV- cattle (Figure 4b; an
example of the gating strategy is shown in Figure 4c).
IgM+ B cells in all samples barely showed PD-1 expres-
sion (data not shown), although CD19+ B cells in human
patients of chronic lymphocytic leukemia strongly
expressed PD-1 [27].
PD-L1 expression analysis in BLV infection had been
performed in our previous report [19]. However, the
question remained whether BLV+ B cells actually express
PD-L1 or not. To activate the expression of the BLV
protein, such as gp51 and to permit detection of the
BLV+ B cells, PBMC were cultivated overnight before
cell staining. BLV-gp51 expression was not detected in
freshly isolated B cells, cultivation of PBMC overnight
resulted in reactivation of gp51 expression (see
Additional file 1) in line with previous findings [28-30].
The PD-L1 expression was able to be detected in gp51+
B cells (Figure 4d). There is no difference in percentages
of PD-L1 expression between gp51+ and gp51– B cells in
BLV+ cattle. The mean percentages of PD-L1+ cells in B
cells from BLV+ cattle were higher compared to those
from BLV- cattle, as described in a previous report [19].
PD-1 blockade upregulates T-cell function in PBMC from
BLV+ cattle
To assess whether PD-1 blockade activates T-cell func-
tion in response to BLV antigen, PBMC from BLV+ cattle
were cultured with BLV-gp51 peptide mixture in the
presence or absence of anti-PD-1 mAb (5D2), and IFN-γ
Ikebuchi et al. Veterinary Research 2013, 44:59 Page 8 of 15
http://www.veterinaryresearch.org/content/44/1/59production and proliferation of lymphocytes were
measured. The IFN-γ production in PBMC was
upregulated by gp51 peptide mixture relative to Flag
peptide (Figure 5a and Additional file 2), indicating that
the anti-gp51 immune reaction was induced by gp51
peptide mixture. As expected, PD-1 blockade addition-
ally enhanced IFN-γ production in the presence of a
gp51 peptide mix, as compared to the treatment with rat
IgG (Figure 5b). The increasing rate of IFN-γ production
in PD-1 blockade was correlated with frequencies of PD-
1 expression in CD4+ T cells (Figure 5c), but not CD8+
T cells (data not shown). On the contrary, one of the
immunoinhibitory cytokines, IL-10 production was not
altered by PD-1 blockade (Figure 5d). Next, proliferation
of lymphocytes was analyzed by CFSE staining. Detec-
tion of proliferating T cells was difficult because there
were very few T cells in cultivated PBMC from BLV-
infected cattle causing abnormal B cell proliferation. So,
the proliferation of lymphocytes other than B cells was
investigated using the gating strategies described in
Figure 1a and 2c. PD-1 blockade in PBMC resulted in anFigure 3 Enhancement of cytokine production by anti-PD-1 mAb in b
four types of anti-PD-1 mAb (20 μg/mL) in the absence (a; n = 8 or 14) or p
measured by ELISA. Statistical comparisons between rat IgG control and an
Differences were considered statistically significant at P < 0.05 (*P < 0.05; **increase in the frequencies of CFSElo IgM- lymphocytes
relative to the treatment of control antibody (Figure 5e).
PD-1 blockade inhibits BLV-gp51 expression and B
cell activation
Next, we evaluated whether PD-1 blockade altered B-
cell activation and BLV expression. The incubation of
PBMC with gp51 peptide mix in the presence of anti-
PD-1 mAb resulted in the reduction of the frequencies
of gp51+ cells in IgM+ B cells (Figure 6a). Because previ-
ous reports showed that B cell activation augments viral
expression ex vivo [31], we hypothesized that one of
the mechanisms responsible for the inhibition of
gp51 expression resulting from PD-1 blockade was
downregulation of B cell activation. To test this hypoth-
esis, the expression of activation markers, WC4 (CD19
like molecule) and CD80, of B cells were measured. PD-
1 blockade resulted in the attenuation of WC4 and
CD80 expression in B cells (Figure 6b, c), and, moreover,
reduction in the expression of BAFF mRNA (Figure 6d),
which is an important cytokine for B cell survival [32].ovine lymphocytes. PBMC were cultivated with rat IgG control or
resence (b; n = 16) of PMA/ionomycin. IFN-γ production was
ti-PD-1 mAb were made using the Wilcoxon matched-pairs test.
P < 0.01).
Figure 4 (See legend on next page.)
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Figure 4 Expression analysis of bovine PD-1 in BLV-infected cattle. (a, b) Percentages of PD-1-expressing CD4+ and CD8+ T cells in PBMC
(a) and LN (b) isolated from BLV- cattle (CD4+ T cells; n = 20 and 31, CD8+ T cells; n = 16 and 31), BLV+ cattle (CD4+ T cells; n = 35 and 15, CD8+
T cells; n = 28 and 15) and BCBL (CD4+ T cells; n = 7 and 6, CD8+ T cells; n = 7 and 6). (c) An example of gating strategies for PD-1 expression in
CD4+ T cells and CD8+ T cells isolated from lymph node of BCBL and BLV- cattle. Values in the quadrant indicate the percentage of the cells in
lymphocytes other than IgM+ B cells. (d) Percentages of PD-L1-expressing gp51+ (n = 5) and gp51- (n = 5) in IgM+ B cells from BLV+ and BLV-
cattle (n = 9). Representative dot plots of PD-L1 staining in gp51+ or gp51- B cells are also shown. Statistical comparisons were made using
one-way ANOVA with Tukey’s test. Differences were considered statistically significant at P < 0.05 (** P < 0.01).
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increased in PBMC treated with anti-PD-1 mAb, as
compared with control antibody (Figure 6e). Finally, to
assess whether PD-1 blockade has a direct effect on B
cells, isolated B cells were cultivated with gp51 peptide
mix in the presence of anti-PD-1 mAb. As expected, the
significant changes in gp51 expression in B cells by the
PD-1 blockade were not observed (Figure 6f ), suggesting
that anti-PD-1 mAb did not directly affect gp51 expres-
sion in B cells.
Discussion
PD-1 on lymphocytes is thought to be a major
immunoinhibitory receptor involved in the maintenance
of peripheral immune tolerance and immune evasion of
tumors and infectious agents [2]. The expression of PD-
1 mRNA was previously analyzed in some animal species
by real-time PCR because of lack of specific antibodies
[17,20]. However, although the real-time PCR method
can be used for quantitative analysis, the method
targeting PD-1 requires attention because several splice
variants and homologs of the human and mouse PD-1
gene have been reported [33-35]. PD-1 mRNA tran-
scripts, in which the third exon of the PD-1 gene encod-
ing the transmembrane domain was spliced out,
encoded a soluble form of PD-1 (sPD-1) [33], and sPD-1
blocked the immunoinhibitory effect of PD-1 expressed
on the T cell membrane [34]. Thus, the primer set must
be designed carefully to amplify only the membrane-bound
form but not the soluble form or other splice variants of
PD-1 mRNA. Expression analysis of membrane-bound PD-
1 antigen by flow cytometry is essential to investigate the
exact immunoinhibitory effect of PD-1 in immune cells. In
this report, we describe the establishment of anti-bovine
PD-1 mAb and confirmed the increased frequency of PD-
1+ T cells in BCBL. We also confirmed the upregulation of
IFN-γ production and proliferation and the inhibition of
BLV-gp51 expression and B-cell activation in PBMC from
BLV+ cattle by the treatment with anti-PD-1 mAb.
The molecular weight of both human and bovine PD-
1 was expected to be approximately 30 kDa by calcula-
tion from their amino acid sequences. However, the
band of human PD-1 was found at about 55 kDa in
western blotting [26]. Also, in this study, bovine PD-1
was detected at about 68 kDa. From these observations,human PD-1 and bovine PD-1 are thought to be heavily
glycosylated, which is consistent with the potential N-
glycosylation sites of human and bovine PD-1.
CD4+ and CD8+ T cells are the main targets of study
when investigating immunoinhibition induced by PD-1
in human and mouse models. In cattle, CD4+ T cells
were the main cells that express PD-1 in freshly isolated
PBMC, but the expression levels were not so high. In
humans and mice, PD-1 expression levels in total CD4+
and CD8+ T cells are also very low, even when detected
by sensitive instruments, such as flow cytometry [26,36].
T cells are divided into naive and different memory sub-
sets by the expression of CD45RO, CD45RA and CCR7,
and the memory T cells express high levels of PD-1 [7].
In this study, PD-1 expression in total T cells or B cells
was investigated, but detailed expression analysis is
needed using many cell markers for clarification whether
PD-1+ CD4+ T cells are the memory T cells or other
phenotype.
Stimulation by PMA/ionomycin strongly enhanced
PD-1 expression in CD4+ and CD8+ T cells and B cells.
These findings agree with previous reports, which indi-
cated that activated T and B cells express PD-1 antigen
[26], perhaps, for the sake of preventing activation-
induced cell death. CD25 is the part of IL-2 receptor
and identified as the classical activation marker. We hy-
pothesized that PD-1 upregulation occurred in stimu-
lated lymphocytes which was detected by CD25
expression. However, the data revealed that CD4+ CD25-
T cells also expressed PD-1 and not all CD8+ CD25+ T
cells and IgM+ CD25+ B cells expressed it 48 h after the
stimulation, suggesting that the cell activation detected
by CD25 was not the single cause of PD-1 upregulation.
More work is needed to clarify the kinetics of induction
of PD-1 expression in each cell population.
In chronic infection or tumors, production of inflam-
matory cytokines and proliferation in response to anti-
gens by pathogen-specific CD4+ or CD8+ T cells were
impaired by the PD-1/PD-L1 pathway. These T cells
failed to eradicate the infected cells or cancer cells, and
PD-1 was the most appropriate marker of these
“exhausted” T cells [9,21]. In this report, BLV infection
was chosen as a typical chronic infection and tumor in
cattle for PD-1 expression and functional analysis. BLV
and HTLV-1 are related deltaretroviruses, and higher
Figure 5 Effect of PD-1 blockade on T-cell function. (a) PBMC from BLV+ cattle were cultured with Flag peptide as negative control and gp51
peptide mix. IFN-γ production was measured by ELISA (n = 13). (b, c, d) PBMC were cultured with rat IgG control or anti-PD-1 mAb (5D2; 20 μg/
mL) in the presence of gp51 peptide mix. IFN-γ and IL-10 production was measured by ELISA (b; n = 22, d; n = 26). Positive correlation between
increasing rate of IFN-γ production and percentages of PD-1+ cells in CD4+ T cells corresponding to Figure 4a (c; n = 22). Correlation statistics
were analyzed using the Spearman correlation. (e) The proliferative responses were evaluated by detection of CFSElo cells in IgM- lymphocytes by
flow cytometry (n = 12). Representative dot plots of CFSE-staining in lymphocytes other than B cells are shown. Statistical comparisons between
rat IgG control and anti-PD-1 mAb were made using the Wilcoxon matched-pairs test. Differences were considered statistically significant at
P < 0.05 (* P < 0.05; ** P < 0.01).
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T cells from blood of HTLV-1-infected patients with
adult T-cell leukemia [36]. The frequencies of PD-1+
cells were also higher in CD4+ T cells in blood and both
CD4+ and CD8+ T cells in tumor-bearing LN from
BCBL than mesenteric LN from BLV+ and BVL- cattle.
These data suggest that anergic T cells, which may be
specific for lymphoma cells, were increased in total
CD4+ or CD8+ T cells in BCBL. Moreover, the frequency
of PD-1+ T cells was higher in tumor-bearing LN than
peripheral blood in cattle with lymphoma, and the same
tendency was reported in patients with metastatic mel-
anoma [37]. Immune tolerance by PD-1 expression in T
cells follows T-cell activation by continued epitoperecognition in peripheral lymphoid tissue [38-42]. Thus,
one can speculate that most tumor infiltrated PD-1+ T
cells could be specific for lymphoma cells, and present
tumor-associated antigen, but fail to be activated
properly by the PD-1/PD-L1 pathway, resulting in the
immune evasion of BLV-induced lymphoma cells.
To verify the relationship between PD-1 expression in
T cells and antigen-specific immunosuppression, PD-1
expression analysis in antigen-specific T cells is required.
Indeed, PD-1 upregulation was mainly observed in CD8+
T cells specific for pathogens causing chronic infection
in various infection and tumors, such as HIV and HTLV
infection and mesenteric melanoma [10,37,43]. In this
study, PD-1 upregulation in total CD4+ and CD8+ T cells
Figure 6 Effect of PD-1 blockade on gp51 expression and B-cell activation. (a, b, c) Percentages of gp51-expressing cells (a; n = 15) and
mean fluorescence index (MFI) of WC4 (CD19 like molecule) (b; n = 12) and CD80 (c; n = 6) in IgM+ B cells were evaluated by flow cytometry in
PBMC treated with rat IgG control or anti-PD-1 mAb (20 μg/mL). Representative contour plots showing gp51 expression (right panels) in PBMC
treated with rat IgG control (upper panels) or anti-PD-1 mAb (lower panels) is shown in (a). No staining was observed in PBMC stained with
isotype control for anti-gp51 mAb (left panels). (d) Expression of BAFF mRNA was evaluated by real-time PCR (n = 12). The results are indicated as
relative change to control (no antibody treatment) when the amount of BAFF mRNA expression is divided by GAPDH mRNA expression. (e)
Percentages of apoptotic cells in IgM+ B cells were measured by flow cytometry. Apoptotic B cells were identified as annexin-V+ 7-AAD- cells
(n = 11). (f) Percentages of gp51-expressing cells were evaluated by flow cytometry in isolated B cells cultivated with rat IgG control or anti-PD-1
mAb (n = 11). Statistical comparisons between rat IgG control and anti-PD-1 mAb were made using the Wilcoxon matched-pairs test. Differences
were considered statistically significant at P < 0.05 (*P < 0.05; ** P < 0.01).
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and PD-1 expression in BLV-specific T cells was not ex-
amined. Detection of BLV-specific T cells would enable
more detailed analysis of PD-1, although the divergence
of gene background of cattle complicates the establish-
ment of MHC-tetramer which is an essential tool for
detection. BLV+ B cells are not eradicated by the im-
mune system and proliferate in lymphoid tissue in vivo
[44], so that BLV-specific T cells from BLV+ cattle
without lymphoma could recognize antigen continu-
ously, express high PD-1 and lapse into an anergic state
by PD-L1 expression in BLV+ B cells.
In BLV+ cattle with advanced stage of the disease, pro-
liferation of CD4+ T cells in response to BLV proteins,
such as gag and env, is impaired [6]. In this study, PD-1
blockade enhanced the IFN-γ production in PBMC in
response to the gp51 peptide mix. Moreover, the in-
creasing rate of IFN-γ production was correlated with
percentages of PD-1+ cells in CD4+ T cells, suggesting
that PD-1 blockade invigorated the function of PD-1+
CD4+ T cells, perhaps gp51-specific T cells. Meanwhile,
IL-10 production was not altered in PBMC by treatment
with anti-PD-1 mAb. Blockade of PD-1/PD-L1 pathway
does not seem to upregulate all functions of PD-1+ T
cells.
On the contrary, PD-1 blockade resulted in the inhib-
ition of gp51 expression, reduced the expression of acti-
vation marker of B cells, WC4 and CD80 and increased
B-cell apoptosis. Although the mechanism of BLV-gp51
expression both in vitro cultivation and in vivo is not
dissolved, B-cell activation by immune-mediated stimu-
lation is known as the important factor for activation of
viral protein synthesis [31]. This study did not demon-
strate that T cells reactivated by anti-PD-1 mAb have a
direct effect on the B-cell activity. However, anti-PD-1
mAb did not directly affect B cells, because recognizable
PD-1 expression was not observed in B cells and PD-1
treatment of isolated B cells did not alter gp51 expres-
sion. Changes in the cytokine environment, such as re-
duction of BAFF or activation of cytotoxic T cells
induced by PD-1 blockade could create a disadvanta-
geous environment for B cells, subsequently resulting in
the reduction of gp51, WC4 and CD80 expression and
increased B-cell apoptosis.
PD-1 is expected to be a potential target for reinvigor-
ating the function of exhausted T cells. Many researchers
have investigated antibody treatment that blocks the PD-
1/PD-L1 pathway [11,43,45], and clinical trials in pa-
tients with cancer who were administered anti-PD-1
antibody are now ongoing [13,14]. Anti-bovine PD-1
mAb upregulated IFN-γ production in PBMC from BLV-
cattle, indicating that the immune reactivation by PD-1
blockade is not a limited phenomenon in BLV infection.
Although it is unknown whether PD-1+ T cells in BLV-cattle are specific for some pathogens, there is the possi-
bility that treatment with these anti-PD-1 mAb could be
applied to new targets of therapy for many types of in-
fection in cattle via upregulation of immune responses.
Moreover, the mAb could promote research regarding
bovine immunology and clarify the mechanisms of dis-
eases that induce immunosuppression.
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